NCT04244825

Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF

A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects With Idiopathic Pulmonary Fibrosis

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Blade Therapeutics · Industry
• Sex: All
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis

Detailed description

This is a Phase 2a, double-blind, placebo-controlled, multicentre, adaptive design study of BLD-2660 in subjects with IPF. The study will include a Screening period, a Treatment period, and a Follow-up period. Data on PK, PD, and biomarker activity will be observed.

Conditions

• Idiopathic Pulmonary Fibrosis

Interventions

Type	Name	Description
DRUG	BLD-2660	BLD-2660 - 150 mg capsules '00' size (PO) BID
DRUG	Control: Placebo	Placebo - 150 mg capsules '00' size (PO) BID

Timeline

• Start date: 2019-12-15
• Primary completion: 2020-09-14
• Completion: 2020-11-05
• First posted: 2020-01-28
• Last updated: 2021-03-04

Locations

1 site across 1 country: United Kingdom